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Abstract 
Introduction: Dermatomyositis is a rare heterogeneous systemic autoimmune disease with multiple 
organ involvement which can result in significant disability and mortality. Despite the lack of placebo-
controlled trials, glucocorticoids are considered to be the mainstay of initial management. Treatment 
strategies are mainly based on uncontrolled studies, evidence based guidelines for treatments do not 
exist. 
Areas covered: This review provides an overview of the currently available pharmacological 
treatments in the field of dermatomyositis including conventional immunosuppressants, biologics 
and topical agents. The role of antibodies in different treatment responses of dermatomyositis 
related clinicoserological syndromes is also discussed. A PubMed search was performed in order to 
find relevant literature for this review. 
Expert commentary: Early recognition and intervention is essential to ameliorate disease outcome. 
Determination of antibodies provide a useful key in diagnosis, clinical manifestations, malignancy, 
prognosis, and treatment response and may lead to wider acceptance of personalized medicine. 
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Corticosteroids with adjunctive steroid-sparing immunosuppressive therapies are recommended to 
treat disease activity, prevent mortality, and reduce long-term disability. Combinations of second-
line therapies or newer third-line therapies are used in severe, refractory, or corticosteroid-
dependent diseases. Further research is required to assess the role of new therapies.  
Keywords: antibodies, anti-MDA5, anti-Mi2, antisynthetase syndrome, anti-TIF1, azathioprine, 
cyclophosphamide, cyclosporine-A, dermatomyositis; intravenous immunoglobuline, rituximab, 
methotrexate, mycophenolate mofetyl, tacrolimus 
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Abbreviations:  
ACR: American College of Rheumatology 
ARS: anti-aminoacyl tRNA synthetases 
ASS: antisynthetase syndrome 
AZA: Azathioprin 
CADM: clinically amyopathic dermatomyositis 
CDASI: cutaneous dermatomyositis disease area and severity index 
CK: creatine kinase 
CI: Confidence interval 
CNI: calcineurin inhibitor 
CTD: connective tissue disease 
CYC: cyclophosphamide,  
CSA: cyclosporine-A 
EULAR: European League Against Rheumatism 
FDA: Food and Drug Administration 
DM: dermatomyositis 
DMARD: disease modifying anti-rheumatic drugs 
DOI: definition of improvement 
GC: glucocorticoids 
HAQ: Health Assessment Questionnaire 
HMGCR: 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
HR: hazard ratio 
HRCT: High Resolution Computer Tomography 
IBM: inclusion body myositis 
IIM: idiopathic inflammatory myopathies  
ILD: Interstitial lung disease 
IMACS: International Myositis Assessment and Clinical Studies Group 
IMNM: immune-mediated necrotizing myopathy 
IV: intravenous 
IVIG: intravenous immunoglobuline 
JDM: juvenile dermatomyositis  
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MAA: myositis-associated antibodies 
MDA5: anti-melanoma differentiation associated gene 5 
MDAAT: Myositis Disease Activity Assessment Tool  
MMT: manual muscle testing  
MSA: and myositis-specific antibodies 
MMF: mycophenolate mofetyl,  
MTX: methotrexate 
NXP2: anti-nuclear matrix protein 2 
PFT: pulmonary function test 
PM: polymyositis 
PRINTO: Pediatric Rheumatology International Trials Organization 
RIM: Rituximab in Myositis Trial 
RP-ILD: rapidly progressive interstitial lung disease 
RTX: rituximab 
SAE: anti- small ubiquitin-like modifier activating enzyme 
SCIG: subcutaneous immunoglobulin  
TAC: tacrolimus 
TIF1γ: anti-transcription intermediary factor 1 gamma 
TIS: total improvement score 
TNF: Tumor necrosis factor 
VAS: visual analogue scale 
  
Ac
ce
pte
d M
an
us
cri
pt
1. Introduction:  
 
Dermatomyositis (DM) is a subtype of idiopathic inflammatory myopathies (IIM), collectively 
known as myositis and encompasses a group of rare heterogeneous systemic connective tissue 
diseases. Based on different clinical and histopathological features, IIM can be classified as 
polymyositis (PM), dermatomyositis, immune-mediated necrotizing myopathy (IMNM) and inclusion 
body myositis (IBM). According to the Bohan and Peter Criteria [1], the diagnosis of DM is based on a 
combination of certain clinical and laboratory features, such as (1) the presence of skeletal muscle 
weakness; (2) elevated serum levels of muscle enzymes; (3) myopathic triad on electromyography; 
(4) characteristic histopathological changes on muscle biopsy; and (5) the presence of characteristic 
skin rashes, including the heliotrope rash or Gottron papules over the joint extensor surfaces.  
Myositis syndromes are the main causes of acquired muscle diseases in adults, but IIMs are 
still rare diseases. The annual incidence of IIM is 2-10 per 1 million and overall prevalence is 50-100 
cases/million inhabitants depending on the data origin [2-5]. The portion of DM among IIM in adults 
is ranging between 26-83 %, depending on genetic, geographic and environmental factors [5-7]. 
Dermatomyositis is the predominant form of myositis seen in children (80%-85% of cases) [8-9].  
Dermatomyositis is a multisystem disorder with a wide variety of clinical manifestations 
including lung, joint, esophageal and cardiac findings; however its hallmark features are the 
characteristic skin manifestations and progressive symmetrical muscle weakness. In some adult and 
juvenile cases, presentation and disease course is variable with different manifestations. Some have 
severe muscle disease at onset, whereas some are amyopathic. Some are more at risk of lung disease 
or inflammatory arthritis, in contrast to those who have more skin involvement with complications 
including ulceration or calcinosis. Treatment responses are also variable in these patients, depending 
on disease phenotype and autoantibody presence. Autoantibodies can be found in specific markers 
for myositis, and schematically can be categorized as myositis-associated antibodies (MAAs) and 
myositis-specific antibodies (MSAs). Around 70 % of adult patients and 60 % of juvenile patients now 
have well-defined autoantibody specificities. An increasing number of MSAs and their corresponding 
autoantigen targets have been identified. MSAs define patients into clinical phenotypes and 
potentially can be used as prognostic and therapeutic markers [10-11].  
Survival ranges from 75% to 90% in patients with adult dermatomyositis and is greater than 
95% in those with juvenile dermatomyositis [12-13]. The low incidence of DM and the non-
availability of validated assessment and improvement criteria of the disease severely hampered the 
conduct of controlled drug studies in the past. Therefore treatment strategies were based on clinical 
observations from case series, rather than randomized trials and remained largely consensus driven. 
Moreover, the heterogeneity, different extramuscular involvement of the disease, and features of 
clinicoserological syndromes affect the survival and treatment response of the individual.  
This review focuses on (1) the different pharmacological agents used in the treatment of DM 
and (2) the different treatment responses of dermatomyositis related clinicoserological syndromes. 
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Body:  
2. Treatment strategy: 
 Until now there have not been any therapies approved for the treatment of DM by the Food 
and Drug Administration or the European Medicines Agency based on randomized controlled trials. 
The reason behind this is the lack of validated clinically meaningful outcomes. In order to adequately 
assess the efficacy of therapy, first of all reliable, validated outcome measures are required. As DM is 
a complex, multisystem disorder, there is no single gold-standard measure for assessing disease 
activity. The International Myositis Assessment and Clinical Studies (IMACS) group has developed a 
consensus on a set of Core Set Domains and Measures for the assessment of disease activity, disease 
damage and patient-reported outcomes in adult and juvenile myositis patients [14]. Disease activity 
assesses the manifestations of myositis which are thought to be reversible and result directly from 
the inflammatory process, whereas disease damage is thought to be those persistent changes in 
anatomy, physiology, pathology or function which result from previously active disease and from 
complications of therapy or other events [15]. The IMACS Disease Activity core set measures are the 
followings: (1) physician's global disease activity assessment by visual analogue scale (VAS); (2) 
patient/parent's global disease activity assessment on VAS; (3) muscle strength measured by manual 
muscle testing (MMT); (4) physical function measured by Health Assessment Questionnaire (HAQ); 
(5) serum levels of muscle enzymes; (6) extra muscular activity: Myositis Disease Activity Assessment 
Tool (MDAAT). The use of these measures is recommended in all myositis therapeutic trials and 
clinical studies, instructions and educational resources are available and the measures have been 
validated by IMACS [15].  
The recent development of American College of Rheumatology/European League Against 
Rheumatism (ACR/EULAR) criteria for minimal, moderate, and major clinical response in adult 
dermatomyositis and polymyositis marks a major advancement in assessing response in myositis 
clinical trials and studies. These response criteria are sensitive and specific and provide a way to 
determine clinically meaningful change corresponding to degree of clinical improvement [16-17]. A 
total improvement score (range 0–100), determined by summing scores for each core set measure, 
was based on improvement in and relative weight of each core set measure. Thresholds for minimal, 
moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score 
(TIS) [16-17].  
The primary goal of therapy is to increase muscle strength, facilitate the management of 
daily activity, treat systemic involvements, and skin rashes, prevent joint contractures and the 
improve the quality of life. The core therapeutic approach remains oral corticosteroid therapy, along 
with adjunctive steroid-sparing immunosuppressive therapies, which are used to treat disease 
activity, prevent mortality, and attempt to reduce long-term disability.  
 
3. Overall management 
 
3.1 Glucocorticoids: 
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The first line therapy of dermatomyositis is glucocorticoid administration. It is widely accepted 
that it improves survival, muscle strength, normalizes muscle enzyme levels, reduces disease activity, 
and disease related disability [18], however no placebo controlled trial with glucocorticoids was 
carried out. The initial dose of prednisone or it’s equivalent recommended as 0.5-1 mg/kg/day, for at 
least 4 weeks and the dose should be tapered monthly by 10-20 % to the minimal effective dose 
based on the improvement of muscle function. When the daily prednisone dose reaches 5–10 
mg/day, the tapering is frequently held for total duration of therapy from 6 to 12 months to prevent 
relapse. Several factors could be contributed to disease response, including disease subtype, 
antibody status and malignancy. In a retrospective cohort study, none of the patients with a long 
delay to diagnosis (greater than 18 months) responded completely, compared with 34% of those 
with a short delay (less than 3 months)[18]. Patients with severe disease manifestations such as 
marked weakness, severe dysphagia or rapidly progressive interstitial lung disease require pulse 
intravenous methylprednisolone (1000 mg daily for three consecutive days) followed by the high-
dose oral glucocorticoid regimen [19]. These patients generally should be started on a steroid-sparing 
immunosuppressive drug.  
 
3.2  DMARDs 
 
Conventional immunosuppressive drugs (disease modifying anti-rheumatic drugs), such as 
methotrexate, azathioprine, cyclosporine-A are considered to be a first line therapies besides steroid 
in patients with myositis. These have steroid sparing effect, also can decrease the steroid related side 
effects, and can treat the extramuscular manifestations.  
There are no prospective, blinded, controlled studies of methotrexate (MTX) in dermatomyositis, 
but limited number of case series indicated that MTX might be a useful drug in DM. In patients with 
JDM, the Pediatric Rheumatology International Trials Organization (PRINTO) study showed that MTX 
is the first line used immunosuppressive drug worldwide [20]. In one retrospective study MTX led to 
a significant reduction of cutaneous dermatomyositis disease area and severity index (CDASI). In 
contrast, the lymphocytic infiltrate in primary skin lesions of MTX responders was significantly more 
pronounced than that in nonresponders [21]. In a retrospective study, response to MTX seemed to 
be better in men than in women [18]. There was a study investigating the safety and efficacy of 
combined MTX + glucocorticoids (GC) treatment compared to GC alone (Prometheus). Twenty-seven 
patients completed, the primary endpoint was the total dose of glucocorticoids administered 
between baseline and the end of treatment, the results were not yet reported [22]. In a retrospective 
study, the 5-year survival was similar among patients treated with MTX and those treated with AZA, 
whereas survival was higher in the MTX group from 5 years onward [23]. In contrast, in a Chinese 
survival analysis study of patients with dermatomyositis showing use of azathioprine had better 
survival [24]. The presence of lung disease might influence the selection of immunosuppressive 
agents, with AZA potentially being chosen for ILD patients to avoid MTX-associated lung injury. In 
addition, although the FDA considered azathioprine a class D drug, there are substantial data 
supporting its safety in pregnancy, whereas MTX is contraindicated [25]. Combination therapy with 
methotrexate and azathioprine could be also considered when patients have failed to respond to 
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either agent alone, as demonstrated in a randomized, crossover study of 30 patients with refractory 
IIM [26]. 
T cells play important role in the pathogenesis of dermatomyositis, thus targeting T cells with 
calcineurin inhibitors, such as tacrolimus (TAC) and cyclosporine-A (CSA) provides an excellent 
therapeutic option in IIM. In a systematic review of 8 non-randomized, mainly retrospective study 
the tacrolimus doses of 0.075 mg/kg/day or 1–3.5 mg/day were given and were administered twice 
daily or once a day. According to the comprehensive analysis of the studies, 93.3 % (42/45) and 64.7 
% (11/17) of patients showed improvement in muscle strength and physical function status [27]. In a 
more recent retrospective study of 66 patients with PM (n=28) and DM (n=38) found that 
concomitant use of systemic tacrolimus with GC provides a favorable outcome, lower frequency of 
relapse and longer periods of remission (P = 0.0001, P = 0.001, respectively) [28]. In a trial comparing 
the effect of cyclosporine-A versus MTX showed no significant differences between the two 
treatment arms, but administration of MTX or CSA to corticosteroids was associated with clinical and 
laboratory improvement [29]. One small retrospective study of patients with DM and acute/subacute 
ILD (n=16) found that initial administration of CSA and prednisolone at the early stage of ILD have 
better outcome in survival rate than prednisolone alone [29]. The same group from Japan found that 
early intervention with prednisolone and CSA improved the findings of PFTs and chest HRCT scans 
and that the level of CSA was significantly correlated with the improvement of PFT findings in 
patients with DM and acute/subacute ILD (n=14) [31]. The favorable effect of intravenous use of CSA 
was demonstrated in another Japanese study in severe DM cases [32].  
Cyclophosphamide (CYC) is an alkylating agent, which is used mainly in patients with DM and 
rapidly progressing ILD and/or vasculitis. Although CYC in PM/DM with interstitial pneumonia 
produced inconsistent results in a few case reports, an open-label study of 17 patients has found 
that, monthly administered IV CYC in different doses and durations improved symptoms, pulmonary 
function tests and HRCT findings [33]. It can be also used in those patients, who develop flare of ILD 
after GC and CSA treatment [32], and in children with severe and refractory JDM, where CYC 
appeared to have provided major clinical benefit with no evidence of serious toxicity in the short 
term [34]. However potentially severe side effects, such as neutropenia, infections, irreversible 
ovarian failure leading to infertility and late malignancy could occur after treatment, the optimal 
dose and duration of the treatment is not defined. Recently, the use of IV CYC according to the Euro-
Lupus Nephritis protocol showed improvement of PFT-s and HRCT findings without any adverse 
events or drug toxicity [35]. 
Mycophenolate mofetil (MMF) inhibits T and B cell proliferation via impeding the guanosine 
nucleotide synthesis. There are no prospective large randomized trials and the results of small case 
series are conflicting. In a study, 10 patients with idiopathic dermatomyositis were treated with 
mycophenolate mofetil in combination with corticosteroids. Successful steroid taper without disease 
relapse was achieved in six patients, but in three patients, treatment was associated with 
opportunistic infections, leading to death in one patient [36]. Another retrospective study found 
MMF therapy useful in patients (n=4) with DM and ILD [37] and in DM with severe skin 
manifestations [38].  
3.3 Intravenous immunoglobulin (IVIG) 
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In addition to its use for the treatment of primary and secondary immunodeficiencies, IVIG is 
increasingly used for immunomodulating therapy in the treatment of patients with a variety of 
autoimmune and inflammatory neurological disorders. However, there is only 1 placebo-controlled 
clinical study in 15 subjects with refractory DM published so far, employing a dose of 2.0 g/kg IVIG or 
placebo for 12 weeks. After a 1-month washout phase the subjects crossed over to the alternate 
therapy [39]. Subjects on IVIG had a significant improvement in muscle strength and neuromuscular 
symptoms in contrast to subjects on placebo. A total of 12 subjects received IVIG of which 9 subjects 
had a major improvement to nearly normal function. In another retrospective study, thirteen 
patients treated with IVIG (2 g/kg, every 4 weeks) for refractory cutaneous dermatomyositis and all 
patient improved [40]. A prospective Japanese trial examined the efficacy of 2 g/kg IVIG once in 
steroid refractory IIM and have found that efficacy rate was 93,3 % (14/15 patient) as assessed using 
MMT [41]. Another open label study found that IVIG as add on treatment with MMF is effective in 
severe and refractory myositis; all the 7 patients (4 PM and 3 DM) achieved complete remission, 
determined by increase of muscle strength and normal CK levels [42]. The use of IVIG was also 
studied in JDM patients. In a large retrospective study 30 steroid refractory patients received IVIG 
and were compared to 48 similar matched controls. IVIG-treated patients maintained similar or 
lower disease activity, despite having greater disease activity at baseline [43].  
Recently, subcutaneous immunoglobulin (SCIG) has been demonstrated to be a valuable 
alternative to IVIG in primary immunodeficiencies. Some advantages linked to SCIG are a more 
favorable side effect profile and better sustained serum IgG levels. A prospective open-label single-
centre study demonstrated significant improvement in muscle enzymes, muscle weakness, quality of 
life, after SCIG administration in seven patients with active and refractory inflammatory myopathies 
[44]. In addition, administration of SCIG was beneficial and safe in maintaining a quiescent disease 
and in inducing a complete remission in moderately active disease in patients with DM or PM [45]. 
Nowadays a number of studies are registered to prove the efficacy of IVIG/SCIG in IIM, one of them is 
prospective, double-blind, randomized, placebo-controlled (NCT02728752).  
 
3.4 Rituximab:  
Rituximab (RTX) is an anti-CD20 monoclonal antibody targeting B cells, which has been 
successfully used in the treatment of several autoimmune diseases. B cells play a critical role in the 
initiation and propagation of the immune response and are specifically implicated in the 
pathogenesis of myositis [46]. Usage of rituximab in refractory IIMs has been reported in several 
small case reports and case series [47]. A small open-label uncontrolled study showed that all 
evaluable patients with dermatomyositis exhibited major clinical improvement, with increasing 
muscle strength [48]. The Rituximab in Myositis (RIM) was the largest study performed in connection 
with inflammatory myopathies [49]. Two hundred patients were enrolled (76 with PM, 76 with DM, 
and 48 with juvenile DM), who had failed response with steroid and another immunosuppressive 
agent. Patients were randomized to receive either rituximab earlyer or rituximab 8 weeks later, and 
glucocorticoid or immunosuppressive therapy was also allowed at study entry. The primary end point 
was to compare the time to achieve the IMACS preliminary definition of improvement (DOI) between 
the 2 groups. The final results did not show difference in the time to improvement (20.2 or 20.0 
weeks), however, 83 % of the randomized refractory patients met the DOI (median time was 20 
weeks). Rituximab was generally well tolerated and safe and it demonstrated a significant steroid-
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sparing effect over the period of the study (mean daily prednisone dose decreased from 20.8 mg at 
baseline to 14.4 mg at the end of the clinical trial). Post hoc analysis showed that presence of an 
antisynthetase, primarily anti–Jo-1, anti–Mi-2, or other autoantibody predicted a shorter time to 
improvement compared to the absence of autoantibodies, and moreover JDM subtype versus adult 
also predicted improvement [50]. The autoantibody levels in myositis subjects (Anti-Jo-1, anti-TIF1-g 
and anti-Mi-2) decreased after B cell depletion and were correlated with changes in disease activity 
[51], which argue for the important role of these autoantibodies in the disease pathogenesis. 
3.5 Other biologics 
Abatacept is a fusion protein between immunoglobulin and the extracellular domain of cytotoxic 
T-lymphocyte antigen 4 that exerts an anti-inflammatory effect by down- regulating T-cell activation. 
A case report of a recalcitrant JDM complicated by ulceration and calcinosis found beneficial effect of 
abatacept [52]. Later a randomized, treatment delayed-start trial was performed to assess the effects 
of abatacept on disease activity and on muscle biopsy features of adult patients with PM and DM. 
Among 20 randomized patients, 17 were included in the analyses and 8 (47%) achieved the DOI after 
6 months of active treatment [53].  
Tumor necrosis factor (TNF)-a may play a role in the pathogenesis of DM [54]. In a pilot study, 
assessing the safety and tolerability of etanercept in dermatomyositis, results showed significant 
difference between the treatment groups favoring etanercept in the time from randomization to the 
first occurrence of treatment failure, but rash worsened in 5 etanercept-treated subjects [55]. In 
addition, etanercept also showed a steroid-sparing effect (median prednisone dose after 24 weeks in 
the etanercept-treated group 24 was 1.2 vs. 29.2mg/day; P=0.02), but only 16 patients were 
randomized, 11 patients received etanercept. In another trial of patients with refractory juvenile DM, 
etanercept did not demonstrate appreciable improvement and some patients noted worsening of 
disease [56]. In addition, several case reports have been published to demonstrate a TNF inhibitor 
induced dermatomyositis [57-58]. As a conclusion, these agents should be considered when other 
therapies are ineffective. 
 
3.6 Topical agents: 
Topical agents could be useful supplementary treatments in diseases, where skin involvement is 
dominant. Ultraviolet radiation intensity was associated with the relative proportion of patients with 
dermatomyositis and with the proportion of patients expressing anti-Mi-2 autoantibodies in the 
United States [7]. The cutaneous manifestations are extremely photosensitive, thus patients should 
be educated on the importance of UVA, UVB, and sun protection factor levels, topical sunscreens are 
commonly used and recommended. Topical steroids are largely used in combination with oral 
treatments. For control of erythema and pruritus associated with inflammatory disease, topical 
corticosteroid treatment is usually necessary, although this should not be used on the face or 
intertriginous areas [59]. Corticosteroid-impregnated tape or topical corticosteroids covered with 
plastic food wrap have been recommended for treatment of refractory or hyperkeratotic lesions [60]. 
Usage of topical calcineurin inhibitors are also reported, amyopathic dermatomyositis and classical 
dermatomyositis patients without muscle disease activity had success with topical 0.1% tacrolimus 
[61-62]. Cases of two DM patients showed beneficial effect of topical pimecrolimus, which may be a 
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therapeutic alternative for the management of the cutaneous lesions of DM [63]. Respecting the 
safety profile of topical calcineurin inhibitors, its use should be considered in both children and 
adults with cutaneous manifestations of dermatomyositis refractory to other treatments. In order to 
use these options as an alternative or adjunctive therapy, however, further randomized controlled 
trials are needed.  
 
4. Dermatomyositis related clinicoserological syndromes:  
Autoantibodies are believed to have a key role in the pathogenesis of myositis and have been 
identified in over 50% of patients with IIM. It has been demonstrated that these autoantibodies 
target both nuclear and cytoplasmic components of the cell and they have traditionally been divided 
into two subsets, myositis-associated autoantibodies (MAAs) and myositis-specific autoantibodies 
(MSAs). These antibodies have been extensively demonstrated to correlate with specific clinical 
manifestations, they are important biomarkers for myositis, aiding in diagnosis and helping to classify 
patients into more homogeneous groups [64]. The antibodies which are associated with 
dermatomyositis and skin involvements are the followings: anti-aminoacyl tRNA synthetases (ARS), 
anti-Mi2, anti-SAE, anti-MDA5, anti-NXP2, and anti-TIF1gamma [65]. 
4.1 Antisynthetase syndrome:  
Anti-ARS autoantibodies are the most frequently detected antibodies in adult patients with 
myositis. According to recent research anti-ARS autoantibodies include anti-Jo-1, anti-PL-7, anti-PL-
12, anti-OJ, anti-EJ, anti-KS, anti-SC, anti-JS, anti-Ha and anti-Zo autoantibodies [66]. The presence of 
these antibodies define a distinct clinical phenotype, antisynthetase syndrome (ASS), which is 
characterized by poor prognosis and multiple organ involvement, such as myositis, ILD, non-erosive 
arthritis, Raynaud’s phenomenon, mechanic’s hand, skin rashes, and fever. ILD is by far the most 
severe manifestation of ASS, occurs in around 80 % of ASS patients, and is associated with high 
morbidity and mortality. A metaanalysis comparing anti-Jo-1-positive and non- Jo-1 ARS-positive 
patients reported an increased likelihood of myositis, arthralgia and mechanics hands in anti-Jo-1-
positive patients, with non-Jo-1 ARS-positive patients having an increased frequency of DM skin 
lesions, fever and ILD [66]. Furthermore, anti-Jo-1-positive patients have been shown to have a 
better 5- and 10-year survival compared to non-Jo-1 ARS-positive patients [67-68]. It is important to 
consider non-Jo-1 ARS in patients presenting with ILD and non-descript CTD symptoms in the 
absence of obvious myositis, even when screening autoantibody tests are negative. The commercial 
availability of more accurate testing and an increased awareness of these patients among 
rheumatologists and pulmonary specialists will likely lead to better patient outcomes and more 
thoughtful treatment strategies [68].  
Survival of patients is mainly determined by the presence or absence of ILD: In a cross sectional 
analysis of 831 patients from a single center revealed that the risk of death was statistically 
significantly higher among participants with ILD compared to those without ILD (HR 2.13. 95 % CI 
1.06-4.25; p = 0.03) [69]. The coexistence of anti-SS-A and anti-Jo-1 antibody may be a good predictor 
for a more coarse and severe ILD in IIM patients who require a more aggressive therapy [70]. The aim 
of management in this population of patients is to reverse disease progression. The pharmacological 
therapy contains immunosuppression; typically including oral immunomodulatory agents, IV 
methylprednisolone and IV CYC. In refractory cases decisions to initiate B cell depletion with 
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rituximab are implemented. RTX seems to be more effective in antisynthetase patients [50, 71, 72], 
thus it is a valuable option in refractory cases.  
 
4.2 Mi-2 
The frequency of anti-Mi-2 is 9–24% in adult IIM and 4–10% in JDM [64]. Clinically, anti-Mi-2 is 
associated with “classic dermatomyositis”, a range of cutaneous features including Gottron’s 
papules, heliotrope rash, V-sign and shawl sign rashes, and cuticular overgrowth [73-76]. These 
patients have more favorable prognosis, milder muscle involvement and a decreased risk of ILD and 
malignancy. Patients with anti-Mi-2 autoantibodies tend to respond well to immunosuppressive 
therapy. In therapy refractor cases RTX seems to be effective. The RIM study demonstrated that the 
presence of anti-Mi-2 autoantibodies predicted a shorter time to improvement compared to the 
absence of these autoantibodies after RTX administration (hazards ratio 2.5, P < 0.01) [50]. 
 
4.3 TIF1gamma 
The target of TIF1γ as a 155 kDa protein with a further 140 kDa band was identified transcription 
intermediary factor 1 gamma [77]. The frequency of anti-TIF1γ is 13–21% in adult and 23–29% in 
juvenile IIM cases [73]. Clinical representation of patients with anti- TIF1γ is DM associated with 
malignancy in adult patients. A meta-analysis reported a sensitivity of anti TIF1γ for diagnosing 
cancer-associated DM was 78% (95% CI 45-94%), and specificity was 89% (95% CI 82-93%). The 
diagnostic OR was 27.26 (95% CI 6.59-112.82) [78]. In juvenile DM patients, anti-TIF-1γ antibodies are 
not associated with malignancy, but rather, with skin ulcerations and more extensive cutaneous 
diseases, without calcinosis [73]. Similarly, calcinosis was negatively associated with TIF1γ antibodies 
in adult patients [79]. In the RIM study, anti-TIF1γ levels were decreased after RTX administration 
and correlated with changes in disease activity [51]. 
4.4 MDA5 
 Anti-MDA5 autoantibodies target melanoma differentiation associated gene 5 (MDA5), a 
cytoplasmic protein, which were originally found in an Asian adult DM cohort [80]. The occurrence of 
the antibody differs in the world. The overall frequency of anti-MDA5 antibodies was significantly 
higher in Chinese patients than in Japanese cohort (36.6 % versus 15.8 %, P < 0.001) [81]. In contrast, 
the frequency is substantially lower in the USA and in European cohorts, only being described in 0–
13% of DM patients [64]. Patients from the East Asian population are reported to have clinically 
amyopathic dermatomyositis (CADM), rapidly progressive ILD (RP-ILD) and poor prognosis [73], 
Chinese tend to have classic DM [81]. Patients from the USA with anti-MDA5 positivity are reported 
to have mild muscle symptoms and DM, which is associated with ulcers; arthritis and ILD. The 
phenotype is frequently a clinical mimic of the antisynthetase syndrome and is not associated with 
rapidly progressive ILD [82]. Ferritin is a useful predictive marker for RP-ILD, and serum ferritin levels 
predict the development and severity of RP-ILD in PM/DM patients and correlate with disease 
activity [83]. The therapeutic strategy in RP-ILD patients with hyperferritinemia and/or anti-MDA5 
positivity might be a combination therapy of corticosteroids, IV CYC, and calcineurin inhibitors (CNI-
s), such as CSA and TAC, and should be immediately administered [83]. However, approximately 
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20%–40% of RP-ILD with anti-MDA5 patients die within 6 months after diagnosis, even if a 
combination therapy of corticosteroids, IV CYC, and CNIs is immediately administered [81, 84]. RTX or 
MMF administration may be considered when RP-ILD is refractory to the therapies described above 
[83]. 
4.5 SAE 
 This antigen is the small ubiquitin-like modifier activating enzyme (SAE). It is almost 
exclusively present in DM with a frequency of 6-8%. Patients with anti-SAE had a high frequency of 
cutaneous lesions including heliotrope and Gottron rash and often develop dysphagia [85-86]. The 
presence of ILD is not common and the prognosis is good [87]. 
 
4.6 NXP2 
 Anti-NXP2 autoantibodies target a 140-kDa autoantigen which known as nuclear matrix 
protein 2 (NXP2). The frequency of this antibody is 1,6-23% [86; 88-89]. Similarly to anti-TIF1γ 
positivity, the adult and juvenile patients also have different phenotypes when this antibody is 
present. Calcinosis is frequently found in both form, but the disease course is severe in adult patients 
and malignancy might be typical, whereas in juvenile cases, malignancy is not frequent. [86; 88-89]. 
Stratification by sex revealed that anti-NXP-2 was specifically associated with cancer in males [90], in 
addition to this intensive cancer search should be performed as part of the diagnostic procedure. 
Treatment strategy in patients with calcinosis is not known. However, different calcinosis-specific 
treatments could be administered, such as calcium-channel blockers, bisphosphonates, warfarin, 
IVIG, colchicine, rituximab, infliximab, sodium thiosulphate, but none of these treatments allowed 
the reduction of calcinosis or the prevention of new sites involved [91]. 
4.7. HMGCR 
Autoantibodies recognizing 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) are 
found in adult myositis patients with immune-mediated necrotizing myopathy (IMNM) and prior 
statin exposure. In a screen of 750 adult myositis patients’ sera no patients had typical DM rashes 
[92]. In contrast, in a cohort of 440 juvenile patients, five were positive and three of them had rashes 
characteristic of juvenile dermatomyositis [93]. In another juvenile cohort, four from 381 patients 
were anti-HMGCR positive, and two of these patients had cutaneous disease [94]. None of these 
patients had prior statin medication. The presence of the antibody was associated with severe 
disease and high CK levels.  
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5. Conclusion 
We can agree based on the prior literary summery that thanks to the lack of controlled trials, 
current therapies used in this disease are mainly based on anecdotes and uncontrolled studies. The 
core therapeutic approach remains oral corticosteroid administration, along with adjunctive steroid-
sparing immunosuppressive agents, such as MTX, azathioprine, CSA and MMF. Determination of 
autoantibodies in the sera of patients with DM is an important key to define disease subtypes, assess 
clinicoserological classification, and it can also help in the decision making to find the best treatment 
option. In refractory cases administration of IVIG, or calcineurin inhibitors might be effective. 
Rituximab is also a valuable option, thus 83% of the patients improved in the RIM trial. Multicenter, 
randomized trials, international collaborations, widespread useage of registries and validated 
outcome measures are required to further facilitate the development of optimal therapeutic 
alternatives in dermatomyositis. 
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6. Expert Commentary 
 There are many fields in the area of pharmacological treatment of dermatomyositis where 
unmet need could be found. The efficacy of currently available medical treatments are mainly based 
on clinical observations on case series and not on randomized, placebo controlled trials. Thus there 
are currently no therapies approved by the Food and Drug Administration or the European Medicines 
Agency. Nevertheless there are many newly available therapies, demonstrating outstanding results in 
distinct disease subtypes. On the other hand there are special scenarios, where the available 
management has poor outcomes, such as calcinosis, or refractory RP-ILD. One key weakness of the 
clinical management is that the diagnosis of the disease have substantial delay in certain cases and 
this leads to irreversible changes in the tissues and results as an incomplete response, despite the 
best treatment regimen. Furthermore, after recognition and diagnosis of the disease, the diagnostic 
procedure should contain the investigation of every potential (extramuscular) organs, which could be 
affected. Detection of recently identified autoantibodies might provide major advantages in the 
diagnosis, organ involvement, complications, prognosis and treatment response, however many of 
them have poor availability and require specialist facilities and training and is unsuitable for use in 
most routine diagnostic laboratories. In addition, these antibodies are currently not involved in the 
classification criteria, which might be changed in the future based on the development and validation 
of IMACS International Myositis Classification Criteria Project. Based on these arguments, we strongly 
recommend the treatment and follow up of DM patients in centers with qualified, experienced 
specialists.  
 The ultimate goal of future research is to find better drugs, which provide a curative solution 
for the patients, if it is possible. To achieve this, intensive collaborations are required between 
clinical and basic science. The exact etiology and pathogenesis of the disease is still unclear. Better 
understanding of the pathomechanism might lead to construction certain molecules which could 
target the immune/non-immune cells, cytokines, transduction, or adhesion molecules, resulting 
sustained remission/cure of the disease. Well designed, prospective trials employing validated 
standardized outcome measures are required to develop an evidence-based approach to the 
treatment of dermatomyositis. One big challenge for future development is the heterogeneity and 
rarity of the disease. Because of that significant progress for an individual researcher at a single 
center could be slow and inadequately powered, hampered by a lack of adequate patient 
information and specimens. To skip this challenge, clinical registries and biorepositories, especially 
international, global registries have proven extremely useful. If clinical data are linked to 
biospecimens, in luding serum, DNA, or tissue biopsy samples, they become powerful tools to 
explore and define disease pathogeneses, biomarkers, and genetic and environmental risk factors 
[95]. The EuroMyositis register [96] is an international collaboration, which has been created in order 
to obtain uniform, longitudinal data over adult and juvenile myositis cases to achieve increased 
knowledge on disease course and prognosis of myositis. The register contains demographic data, 
laboratory parameters, diagnostic results, disease activity and damage data according to the IMACS 
core set measures. Information from treatment and longitudinal data of the disease course in 
combination with research purposes might help to face the abovementioned challenges.  
 There are some encouraging research projects with molecules targeting key pathogenetic 
pathways, including interferon signature, lymphocyte recirculation, T-cell interactions, toll-like 
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receptors, complement components, which may hold promise but require further investigation in 
myositis.  
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7. Five year view 
There are some promising preliminary data, which argue for that in five years from this point, 
new, validated classification criteria will be used for diagnosing inflammatory myopathies. Results 
from well powered ongoing studies using recently developed clinical response criteria might have 
potential for approval of a drug for the treatment of myositis. Better availability and further 
development of imaging (MRI, PET), and serum biomarkers will possess a greater impact in diagnosis 
and treatment response. With more widespread useage of international registries and IMACS 
consensus-derived disease activity measures will provide a major advancement understanding 
disease pathogeneses and will define the optimal therapy in the future.  
 
8. Key issues 
• The primary goal of pharmacological therapy is to normalize muscle strength, prevent joint 
contractures, treat systemic involvements and skin rashes and to improvement the quality of 
life.  
• Corticosteroids are still the first-line treatment of the disease with combination of 
conventional immunosuppression, such as MTX, azathioprine, or cyclosporine-A. 
• Determination of myositis specific antibodies provides a useful key in diagnosis, clinical 
manifestations, malignancy, prognosis and treatment response in dermatomyositis patients. 
• Early detection and treatment of life-threatening organ involvement is crucial to decrease 
mortality 
• Rituximab and IVIG has good results in refractory cases, with certain autoantibody positivity, 
but there is a need for larger randomized controlled trials.  
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